Development and characterization of polymer lipid hybrid nanoparticles for oral delivery of LMWH
Source abstract
Abstract
The present study aimed to develop an improved oral delivery system for low-molecular-weight heparin (LMWH), novel polymer lipid hybrid nanoparticles were developed. LMWH loaded chitosan polymer lipid hybrid nanoparticles (LMWH-CS-PLNs) were developed using double emulsification and solvent evaporation method. The performance of developed formulations was evaluated by using in vitro and in vivo behavior, such as drug release studies, in vitro permeation study, in vivo venous thrombolytic study, in vitro uptake studies by using intestinal epithelium resembling Caco-2 cell lines. The new CS-PLNs might provide an effective strategy for oral delivery of LMWH with improved encapsulation efficiency as compared to CS-NPs and SA-LNPs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Heparin-Induced Thrombocytopenia and Thrombosis · Advanced Drug Delivery Systems · Platelet Disorders and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Nanomedicine Research Centre, I.S.F. College of Pharmacy, Moga, India;
Dr. Reddy’s Laboratories Limited, Hyderabad, India
References (33)
Show source-provided references
1. Agarwal V · Pharm Technol · 2001 · 10 · 76
2. 10.1016/j.jacc.2007.02.01310.1016/j.jacc.2007.02.013 ↗
3. 10.1016/j.jacc.2004.07.01410.1016/j.jacc.2004.07.014 ↗
4. 10.1016/j.ijpharm.2013.08.03710.1016/j.ijpharm.2013.08.037 ↗
5. 10.1007/s11095-008-9769-y10.1007/s11095-008-9769-y ↗
6. 10.1056/NEJM20010301344090210.1056/NEJM200103013440902 ↗
7. 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-410.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4 ↗
8. 10.1016/j.biomaterials.2009.08.03010.1016/j.biomaterials.2009.08.030 ↗
9. 10.1016/j.colsurfb.2011.02.03310.1016/j.colsurfb.2011.02.033 ↗
10. 10.1378/chest.08-065610.1378/chest.08-0656 ↗
11. 10.3109/21691401.2014.95172110.3109/21691401.2014.951721 ↗
12. 10.1016/j.bmc.2005.08.00410.1016/j.bmc.2005.08.004 ↗
13. 10.1016/j.jconrel.2006.03.02010.1016/j.jconrel.2006.03.020 ↗
14. 10.1159/00002240010.1159/000022400 ↗
15. 10.1016/j.jconrel.2012.09.01310.1016/j.jconrel.2012.09.013 ↗
16. 10.1016/j.jconrel.2009.05.02910.1016/j.jconrel.2009.05.029 ↗
17. 10.1161/hc0202.10198810.1161/hc0202.101988 ↗
18. 10.1378/chest.08-065810.1378/chest.08-0658 ↗
19. 10.2131/jts.32.41110.2131/jts.32.411 ↗
20. 10.1021/bc100594v10.1021/bc100594v ↗
21. 10.1016/j.jconrel.2007.08.00710.1016/j.jconrel.2007.08.007 ↗
22. 10.1016/S0140-6736(98)04298-610.1016/S0140-6736(98)04298-6 ↗
23. 10.1345/aph.1A46110.1345/aph.1A461 ↗
24. 10.1023/A:101582941265810.1023/A:1015829412658 ↗
25. Mukherjee S · Pharmabit XV · 2007 · 1 · 53
26. 10.1021/mp200109m10.1021/mp200109m ↗
27. 10.1016/j.ijpharm.2011.10.04810.1016/j.ijpharm.2011.10.048 ↗
28. 10.1016/j.nano.2008.08.00310.1016/j.nano.2008.08.003 ↗
29. Ramadan A · Int J Nanomed · 2011 · 6 · 2941
30. 10.1016/j.jconrel.2008.03.01310.1016/j.jconrel.2008.03.013 ↗
31. 10.1042/bj2003125310.1042/bj20031253 ↗
32. 10.2174/15734130878359181610.2174/157341308783591816 ↗
33. 10.1208/s12249-012-9854-810.1208/s12249-012-9854-8 ↗